Posts Tagged With 'FDA regulatory process'

  • Jun
  • 11
  • 2012

GRAS – One of FDA’s Most Widely Misunderstood Acronyms (Part 3)

The third installment of this series addresses the misconception that in order to be designated “GRAS,” a substance must have been extensively tested and definitively proven to be safe. Many substances have been designated GRAS for their intended use(s) based solely on knowledge of their common use in foods prior to 1958. The presumption of safety for such substances is based on the assumption that a history of safe use adequately predicts future safe use provided that the level and type of use remains essentially the same. For these substances, the absence of a safety concern in the past obviates the need for extensive testing.

Many GRAS substances do not, however, have a history of common use in foods prior to 1958 and GRAS status has been affirmed based on “scientific procedures.” In this context, “scientific procedures” refers to human, animal, analytical, and other scientific studies appropriate to establish the safety of a substance. However, even for substance affirmed to be GRAS based on scientific procedures, this does not necessarily mean that a full battery of safety studies has been completed.

Review of the safety assessments made by the Select Committee on GRAS Substances (SCOGS) in the 1970s for substances later affirmed as GRAS, shows that in many cases safety judgments were made in the absence of a complete safety study dataset. In some cases, the design of toxicity studies was not optimal (e.g., incomplete assessment of usual safety endpoints or small numbers of animals). In other cases, some types of safety studies were missing (e.g., the absence of reproduction studies). In fact, some substances were determined by SCOGS not to present a safety risk with little toxicity data on the specific substance. Safety assessments for chemicals with only very limited substance-specific safety studies may have been based on data showing common metabolites with other more fully-studied substances or on known exposures through the diet to the constituents parts of other GRAS substances (e.g., for salts). These types of arguments supporting safety are widely accepted by qualified experts and support the finding that many substances are GRAS. Ultimately, it is the weight of the available evidence that determines whether a substance is GRAS. Many GRAS substances have been extensively studied for safety and that information constitutes the basis for their GRAS determinations. However, it is important to recognize that a GRAS designation does not necessarily mean that a substance has been thoroughly tested for safety.

Posted by Carrie Rabe, Senior Consultant. For more information, please contact Carrie atcarrie.rabe@weinberggroup.com.

  • Jun
  • 04
  • 2012

Please Join Us For Our Next Webinar: Ensuring Successful FDA Meetings

Please Join Us For Our Next Webinar: Ensuring Successful FDA Meetings

“Ensuring Successful FDA Meetings”
Wednesday, June 20, 2012
12 p.m. (EDT) | 9 a.m. (PDT) | 5 p.m. (GMT)

Online Registration

FDA meetings, regardless of when they occur — from pre-IND, to End-of-Phase 2, to pre-NDA meetings — can make or break your chances of bringing your product to final approval. Ensuring successful meetings is therefore a key part of your overall product development plan. Please join:

Joel Falk, EVP of Product Regulation & Compliance, and Lauren Wind, Senior Consultant, as they discuss key tactics, such as:
• Assuring your submissions provide compelling support to your goals for the meeting
• Structuring your questions to maximize unambiguous responses
• Preparing for the actual meeting — the “Tiger Team”
• Deciding whether to commit or not to commit
• How to best utilize the participants on your side of the table
As well as other methods to increase your success with the FDA.

This complimentary, one-hour webinar is designed to help life science executives understand how to maximize success when meeting with FDA regulators.

To join the webinar, please register here. Upon receipt of registration, a dial-in number and log-in information will be sent.

  • Mar
  • 26
  • 2012

You Do Have a Voice – The FDA Rulemaking Process

Did you know that the FDA Rulemaking Process allows for the public to comment before procedural and scientific requirements go into effect? This is the case for both the debut and amendments to regulations and guidance documents. The Agency requests feedback from individuals and companies involved in applying the requirements to their work to ensure that the requirements maximize the benefit to public health while minimizing the burden for implementation experienced by those impacted by the proposed rule or guidance.

The best way to learn about pending proposed rules and guidances is by regularly reading the Federal Register. When a new or amended regulation or guidance is proposed, it will be published in the Federal Register and a docket will be opened for comment at http://www.regulations.gov. The Federal Register notice may limit the areas comments are being solicited for, as in the case of an amendment or when considering time limitations for a public workshop. Sometimes the agency will even hold public workshops on the subject to present their point of view and to gain input from the public prior to issuing a regulation or guidance for comment. Such a meeting would also be announced in the Federal Register.

In the process of finalizing the regulation or guidance document, the Agency will publish a response to all comments received and describe how they were addressed in the final regulation/guidance.

There have been several prominent rules and guidances related to FDA activities opened for comment in the last year. A partial list is provided below, with the intent to show the wide range of items that fall under the rule-making process. There are many dockets that remain open for comment, including the recently released bioequivalence guidance documents.

Regulations
21 CFR Parts 50 and 56
Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators (Docket closed to comments October 26, 2011)

21 CFR Part 316
Orphan Drug Regulations (Docket closed to comments January 17, 2012)

Draft Guidances
Draft Guidance for Industry; Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations (Docket open for comment until May 12, 2012)

Draft Guidance for Industry on Implementation of Biologics Price Competition and Innovation Act of 2009 (April 16, 2012)

Draft Guidance for Industry on Quality Considerations in Demonstrating Biosimilarity to Reference Protein Product (Docket open for comment until April 16, 2012)

By becoming actively involved in the federal rulemaking process you can help ensure that the umbrella of regulations and guidances you must consider in your work are suitable for “real world” application.

Posted by Theresa Allio, Senior Consultant. For more information, please contact Theresa at theresa.allio@weinberggroup.com.

Posts by Date

June 2013
M T W T F S S
« Jul    
 12
3456789
10111213141516
17181920212223
24252627282930

Recent Comments